Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.
Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.
Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).
Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.
Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.
Renata Block, PA-C, analyzes a study on how vitiligo affects different socioeconomic groups disproportionately.
Gary M. Owens, MD, discusses the economic costs associated with vitiligo and the impact this disease has had on the US health care system in general.
Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.
Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.
Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial diagnosis experience. Jennifer Holman goes on to describe how different patient populations struggle to access quality care.
Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.
Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.
Audrey Dean and her dermatologist, Jennifer Holman, MD, FAAD, discuss the importance of having a network of support when diagnosed with atopic dermatitis.
Chesahna Kindred, MD, MBA, FAAD, and Renata Block, PA-C, review areas of the body that are typically affected, and are more problematic to manage, in patients with vitiligo. Comorbidities that put certain patients at higher risk than others are also discussed.
A panel of experts discuss the diagnosis and pathophysiology of vitiligo.
Raj Chovatiya, MD, PhD; and Boni Elewski, MD, define what differentiates generalized pustular psoriasis (GPP) from other forms of psoriasis and discuss tools for diagnosing GPP.
Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.
Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.
Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).
Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.
Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.
Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial symptoms and how the disease impacted her quality of life (QoL). Jennifer Holman reflects on how her practice and approaches have changed as she learned more about the daily impact of atopic dermatitis.
A dermatologist and her patient discuss the pathophysiology and major comorbidities of atopic dermatitis (AD), highlighting the main differences between adult and adolescent AD.
Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.
Erin Boh, MD, discusses the role of steroid administration and withdrawal as a trigger for GPP, highlighting the importance of physician awareness of external influences initiating this condition.
Experts discuss the selectivity of Janus Kinase (JAK) inhibitors and considerations when selecting treatment for atopic dermatitis (AD).
Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the nuances of box warnings and how clinicians should assimilate these risk factors in the treatment of atopic dermatitis (AD).
Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.
Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.
Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.
